药物诱导的Ivermectin药物诱导的肝损伤
Mark Sonderup1, Washington Mudini2, Wendy Spearman3
1Division of Hepatology and Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital. msonderup@samedical.co.za.
概括
用于预防COVID-19的IVERMECTIN与患有黄和肝损伤的患者有关. 用皮质类固醇治疗解决了损伤,突出显示了甲的潜在肝毒性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 尽管没有证实有效性,但艾弗梅克被广泛用于COVID-19的预防和治疗.
- 药物诱导性肝损伤 (DILI) 是许多药物的重要关注点.
研究的目的:
- 报告一种因ivermectin诱导的肝损伤病例 (IILI).
- 描述IILI的临床表现,组织学发现和管理.
主要方法:
- 一个病人的病例报告在使用ivermectin后出现黄和肝损伤.
- 肝脏组织学的综述显示了带有胆管炎和胆固醇性胆管炎的门口和叶片炎症.
- 用低剂量的皮质类固醇进行临床管理.
主要成果:
- 患者在开始服用ivermectin作为COVID-19预防药物三周后出现了黄和肝损伤.
- 肝脏活检显示了门口和叶片炎症,胆管炎和胆管病变.
- 皮质类固醇治疗和戒断后症状消失.
结论:
- 艾弗梅克丁可能会导致肝损伤,呈现为胆固醇和肝细胞模式.
- 皮质类固醇在治疗因ivermectin引起的肝损伤方面可能有好处.
- 需要进一步调查ivermectin的肝毒性.
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
1.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.6K
Hepatic Drug Excretion: Influencing Factors
165
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
165
Anticholinesterase Agents: Poisoning and Treatment
927
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
927
Diseases of the Liver and Gallbladder
700
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
700
Esophageal Varices-II: Clinical Features and Management
100
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
100
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K


